Evaluation of the Clinical Performance of 7 Serological Assays for SARS-CoV-2 for Use in Clinical Laboratories

Author:

Plaga Alexis1,Wei Ruhan1,Olson Elizabeth1,Payto Drew1,Harrington John1,Nwe-Kissig Pyik That1,Strizzi Michelle1,Zilka Sarah1,Ko Jennifer1,Colón-Franco Jessica M1

Affiliation:

1. Department of Pathology and Laboratory Medicine, Cleveland Clinic, OH, USA

Abstract

Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological assays have emerged as a response to the global pandemic, warranting studies evaluating their clinical performance. This study investigated 7 commercially available SARS-CoV-2 serological assays in samples from noninfected individuals and hospitalized patients. Methods SARS-CoV-2 qualitative serological assays by Abbott (IgG), Beckman (IgG), DiaSorin (IgG), EUROIMMUN (IgG and IgA), Roche and Bio-Rad (Total) were evaluated using specimens collected pre-December 2019 (n = 393), from nucleic acid amplification testing (NAAT) negative patients (n = 40), and from 53 patients with COVID-19 by NAAT collected 3–21 days post-onset of symptoms (POS) (N = 83). Negative agreement (NA), positive agreement (PA), and positive and negative predictive values (PPV and NPV) at prevalences of 5% and 10% were calculated. Results The overall %NA; 95% CI in the negative samples were: Roche 99.8%; 99.3–100.2, Beckman 99.8%; 98.7–100.0, Abbott and Bio-Rad 99.3%; 98.0–99.9, DiaSorin 98.4; 97.2–99.6, EUROIMMUN IgG 97.5%; 95.5–98.7, and EUROIMMUN IgA 79.7%; 75.9–83.5), accounting for positive/equivocal results as false positives. The %PA; 95% CI in samples collected 14+ days POS (n = 24) were: Bio-Rad 83.3%; 68.4–98.2, Abbott and Roche 79.2%; 62.9–95.4, EUROIMMUN IgA 70.8%; 52.6–89.0, Beckman 58.3%; 38.6–78.1, DiaSorin 54.2; 34.2–74.1, and EUROIMMUN IgG 50.0%; 30.0–70.0, accounting for negative/equivocal results as false negatives. NPVs ranged from 97.4%–98.9% and 94.7%–97.7% for prevalences 5% and 10%, respectively. PPVs ranged from 15.5%–94.8% and 27.9%–97.4% for prevalences 5% and 10%, respectively. Conclusion The Roche and Beckman assays resulted in fewer false positives, followed by the Bio-Rad and Abbott assays. While the Bio-Rad assay demonstrated higher antibody detection in COVID-19-positive patients, PA claims cannot be established with a high level of confidence in our sample population.

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Reference20 articles.

1. SARS-CoV-2 serology: much hype, little data;Farnsworth;Clin Chem,2020

2. Rapid roll out of SARS-CoV-2 antibody testing: a concern;Andersson;BMJ,2020

3. Clinical application of serologic testing for coronavirus disease 2019 in contemporary cardiovascular practice;Damluji;J Am Heart Assoc,2021

4. Infectious Diseases Society of America Guidelines on the diagnosis of COVID-19;Hanson;Clin Infect Dis,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3